Comparative estimation of general and local humoral immunity indicators in connection with local immunotherapeutic treatment.
All classes of immunoglobulins in blood and in the nasal secretions of 75 patients were studied in different phases of disease. There were 20 healthy persons in the control group. Forty patients were treated by preseasonal local immunotherapy through the application of water-salt extracts of pollen allergens intranasally, with the help of drops and aerosol during 2 years. It was found that the patients had a high level of total IgE in the nasal secretion, both in the phase of remission and especially in the phase of exacerbation, though the concentration of IgE in the nasal secretion, on the whole, was several times lower than in serum. Quantification of the level of IgE in the nasal secretion can be recommended to diagnosis allergy, "in vitro". The level of sIgA in the nasal secretion of the patients with pollen allergy was lower in comparison with the test group of healthy persons, being most remarkable in the phase of exacerbation. Patients with pollen allergy had a heightened level of IgD in blood with a marked reliability in the exacerbation phase. IgD was not detected in the nasal secretion. Local immunotherapy was found to have a high effectiveness of 80% after one course of treatment, and nearly 95% success with two courses. Therefore, we consider that local immunotherapy should be widely used. With the background of the local immunotherapy there were changes in the concentration of immunoglobulins, mainly in the nasal secretion of the immunoglobulins. IgE in the nasal secretion was lowered to a great extent after two courses of treatment. sIgA after local immunotherapy had a tendency to increase considerably after two courses of treatment. The increase of sIgA level and the lowering of IgE in the nasal secretion can be considered as immunologic criteria of local immunotherapy effectiveness.
Gurgenidze
G V
GV
Department of Allergology, Medical State Institute, Tbilisi, USSR.
Baraban
E I
EI
Gamkrelidze
A G
AG
D000281:Administration, Intranasal; D000485:Allergens / Q000008:administration & dosage; D000917:Antibody Formation; D001826:Body Fluids / Q000276:immunology; D003888:Desensitization, Immunologic; D006801:Humans; D007111:Immunity, Cellular; D007073:Immunoglobulin E / Q000032:analysis; D007136:Immunoglobulins / Q000032:analysis*; D009297:Nasal Mucosa / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000628:therapy
D000485:Allergens; D007136:Immunoglobulins; D007073:Immunoglobulin E